Education
About Us
Working with TipRanks
Follow Us
Icecure Medical Ltd. (ICCM)
NASDAQ:ICCM
ICCM Stock Chart & Stats
$0.86
-$0.06(-4.41%)
At close: 4:00 PM EST
$0.86
-$0.06(-4.41%)
Day’s Range― - ―
52-Week Range$0.59 - $1.63
Previous CloseN/A
Volume318.06K
Average Volume (3M)355.64K
Market Cap
$45.65M
Enterprise Value$59.84M
Total Cash (Recent Filing)$10.01M
Total Debt (Recent Filing)$288.00K
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
Mar 26, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding68,693,054
10 Day Avg. Volume339,587
30 Day Avg. Volume355,645
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)8.11
Price to Sales (P/S)17.01
P/FCF Ratio-4.43
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue20.11
Enterprise Value/Gross Profit57.37
Enterprise Value/Ebitda-3.96
Forecast
1Y Price Target
$2.75Price Target Upside219.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$3.81M
Bulls Say, Bears Say
Bulls Say
Market StrategyICCM's commercial strategy is enhanced by identifying 20 of 30 sites for its post-market study, where procedures will be reimbursable, supporting broader utilization.
Regulatory ApprovalsThe ProSense system received regulatory approval in Switzerland for treating various tissues, which is expected to bolster its market presence.
Revenue GrowthProSense's FDA marketing authorization for early-stage breast cancer is seen as a meaningful milestone that should drive revenue growth.
Bears Say
Regulatory RequirementsThe FDA has requested a post-market surveillance study, requiring IceCure to conduct additional research with 400 patients at 30 sites.
Icecure Medical News
ICCM FAQ
What was Icecure Medical Ltd.’s price range in the past 12 months?
Icecure Medical Ltd. lowest stock price was $0.59 and its highest was $1.63 in the past 12 months.
What is Icecure Medical Ltd.’s market cap?
Icecure Medical Ltd.’s market cap is $45.65M.
When is Icecure Medical Ltd.’s upcoming earnings report date?
Icecure Medical Ltd.’s upcoming earnings report date is Mar 26, 2026 which is in 87 days.
How were Icecure Medical Ltd.’s earnings last quarter?
Icecure Medical Ltd. released its earnings results on Nov 19, 2025. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.01.
Is Icecure Medical Ltd. overvalued?
According to Wall Street analysts Icecure Medical Ltd.’s price is currently Undervalued.
Does Icecure Medical Ltd. pay dividends?
Icecure Medical Ltd. does not currently pay dividends.
What is Icecure Medical Ltd.’s EPS estimate?
Icecure Medical Ltd.’s EPS estimate is -0.05.
How many shares outstanding does Icecure Medical Ltd. have?
Icecure Medical Ltd. has 68,693,054 shares outstanding.
What happened to Icecure Medical Ltd.’s price movement after its last earnings report?
Icecure Medical Ltd. reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -2.778%.
Which hedge fund is a major shareholder of Icecure Medical Ltd.?
Currently, no hedge funds are holding shares in ICCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Icecure Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.75 (219.77% Upside)
$2.75 (219.77% Upside)
Hedge Fund Trend
Decreased
By 11.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.52%
12-Months-Change
Fundamentals
Return on Equity
-157.91%
Trailing 12-Months
Asset Growth
-1.31%
Trailing 12-Months
Company Description
Icecure Medical Ltd.
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
ICCM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook due to the significant milestone of FDA marketing authorization for ProSense, opening up substantial market opportunities and driving global interest. Financially, the company has improved its cash position, although revenue and gross margin have seen declines. Overall, the highlights of strategic achievements and market potential outweigh the current financial challenges.View all ICCM earnings summariesICCM Stock 12 Month Forecast
Average Price Target
$2.75
▲(219.77% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.12% Other Institutional Investors
99.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---